Immune checkpoint inhibitors in pediatric patients with melanoma: a systematic literature review.

IF 1 Q4 ONCOLOGY Melanoma Management Pub Date : 2024-12-01 Epub Date: 2024-08-26 DOI:10.1080/20450885.2024.2382075

Charmy Vyas, Andriy Moshyk, Gina Fusaro, Stergios Zacharoulis, Mir Sohail Fazeli, Nishu Gaind, Shirin Behyan, Pratik Thakkar

引用次数: 0

Abstract

Aim: This study summarized the existing evidence on the outcomes and safety of anti-PD-1s, anti-PD-L1s and anti-CTLA-4s in pediatric patients with melanoma.Materials & methods: MEDLINE^® and Embase were searched from database inception to 01-12-2023.Results: Of 1537 records identified, 27 studies (k) of 64 patients were included. Most studies were case reports (k = 16). All studies used anti-PD-1s (nivolumab, pembrolizumab) alone or anti-CTLA-4s (ipilimumab). Survival outcomes (k = 7), response outcomes (k = 15) and adverse events (k = 16) varied. Safety profiles of anti-PD-1s and anti-CTLA-4s were broadly similar to that seen in adults.Conclusion: Despite scarce, heterogenous data, this review can be a reference for clinicians. Future clinical trials should include adolescents to grow the evidence base on immune checkpoint inhibitors in pediatric melanoma.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

求助全文

约1分钟内获得全文去求助

来源期刊

Melanoma Management ONCOLOGY-

CiteScore

5.10

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Skin cancer is on the rise. According to the World Health Organization, 132,000 melanoma skin cancers occur globally each year. While early-stage melanoma is usually relatively easy to treat, once disease spreads prognosis worsens considerably. Therefore, research into combating advanced-stage melanoma is a high priority. New and emerging therapies, such as monoclonal antibodies, B-RAF and KIT inhibitors, antiangiogenic agents and novel chemotherapy approaches hold promise for prolonging survival, but the search for a cure is ongoing. Melanoma Management publishes high-quality peer-reviewed articles on all aspects of melanoma, from prevention to diagnosis and from treatment of early-stage disease to late-stage melanoma and metastasis. The journal presents the latest research findings in melanoma research and treatment, together with authoritative reviews, cutting-edge editorials and perspectives that highlight hot topics and controversy in the field. Independent drug evaluations assess newly approved medications and their role in clinical practice. Key topics covered include: Risk factors, prevention and sun safety education Diagnosis, staging and grading Surgical excision of melanoma lesions Sentinel lymph node biopsy Biological therapies, including immunotherapy and vaccination Novel chemotherapy options Treatment of metastasis Prevention of recurrence Patient care and quality of life.